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1. Introduction 
Fabry’s disease (FD) is a rare inborn error of glycosphingolipid catabolism can lead to renal 
failure. The life expectancy is reduced for both genders, and the major causes of death 
include cardiac death, stroke, or the consequences of end stage of renal disease. This article 
summarizes the current knowledge about FD and the treatment of kidney transplantation 
and enzyme replacement therapy in FD. 
2. About Fabry’s disease  
FD is a rare sphingolipidosis related and X-linked disorder of glycosphingolipid catabolism 
caused by deficient lysosomal α-galactosidase A activity(Fig.1). Deficiency of the enzyme 
leads to progressive accumulation of the glycosphingolipid globotriaosylceramide (Gb3) in 
vascular endothelia, heart tissue, connective tissue, peripheral nerves, and the kidneys 
(Table.1, Fig.2). Male patients typically develop painful acroparesthesia followed by 
proteinuria, renal failure, cardiac hypertrophy and cerebral white matter lesions. Females 
are carriers and may present a wider range of symptoms(Fig.3,4). The incidence has been 
estimated to be 1:117,000 live births and 1:50,000 males. Registries of dialysis patients from 
the United States and Europe indicate that FD is the cause of end-stage renal disease (ESRD) 
for approximately 0.2% of patients on dialysis(Fig.5). Renal disease of some form occurs in 
most patients, with ESRD a common manifestation in hemizygous males that may develop 
by the fourth to fifth decade of life. The clinical course in heterozygous female patients 
involves a delayed onset of symptoms and milder progression, although some female 
patients present with symptoms similar to those seen in classically affected male patients. 
The analysis of 197 kidney transplant recipients with FD indicates that they have superior 
graft survival and similar patient survival compared with patients with other causes of 
ESRD. However, Fabry patients had a higher risk of death compared with a matched cohort 
of patients with other causes of ESRD. The median lifespan is 50 years for affected male 
patients and 70 years for female patients. Current therapy for ESRD in patients with FD 
involves renal transplantation and enzyme replacement therapy (ERT). 
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Fig. 1. If a male with Fabry disease and an unaffected (non-carrier) female have children, all 
of their daughters will be Fabry carriers and none of their sons will be affected with Fabry 
disease. 
 
Table 1. The classification of sphingolipidosis. 
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Fig. 2. The classification of sphingolipidosis. 
 
 
      
Fig. 3. Clinical features of Fabry’s disease; angiokeratomas. 
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Fig. 4. Clinical features of Fabry’s disease; corneal and lenticular opacities. 
 
 
Fig. 5. Ultra structural changes in glomerulus with FD with myelin-like inclusions and 
subendothelial deposits. 
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3. Renal transplantation in patient with Fabry’s disease 
Renal transplantation was known to be effective for FD, as previous reports demonstrated 
that the procedure provided equivalent 5-year patient and graft survivals, as well as 
improvement of overall prognosis in patients with ESRD due to FD. In contrast, another 
study found that a renal allograft could not repair the deficient enzyme activity of α-
galactosidase A and noted that the accumulation of Gb3 impaired renal function, which 
might signify the possibility of recurrence of FD in the renal allograft. According to a 
previous study from the European Dialysis and Transplant Association/European Renal 
Association Registry, graft survival at 3 years in 33 patients with FD was not considered as 
inferior to that of patients with other nephropathies (72% vs. 69%), and patient survival after 
transplantation was comparable to that of patients aged under 55 years with non-Fabry 
nephropathies. Excellent graft and patient survival were also reported from the US Renal 
Data System Registry. FD is therefore not considered a contraindication for renal 
transplantation. Although a case study has shown that the disease may recur in the 
transplanted organ, another case study has shown no evidence of disease recurrence in a 
renal biopsy 8 years after transplantation. A further case study showed extensive Fabry-
related renal changes in a renal biopsy from a patient who had received a graft from his 
sister who was heterozygous for the disease. 
4. The efficacy of enzyme replacement therapy (ERT) 
Enzyme replacement therapy (ERT) for the treatment of Fabry’s disease was first performed 
in the 1970s, however, open-label phase 2 trials were not performed until the 2000s. ERT 
using recombinant human alpha-galactocidase A (generic names agalsidase alpha and 
agalsidase beta) was approved for use in Europe in 2001 and in the United States in 2003. 
Initial randomised controlled trials (RCT) showed that 69% of the treatment group was free 
of renal microvascular endothelial deposits of globotriaosylceramide (primary endpoint) 
versus no change in the placebo group after 20 weeks (p < 0.001). Although there did not 
appear to be a difference in quality of life as assessed by the SF-36, another RCT showed a 
statistically significant decrease in pain severity and improvement in quality of life (primary 
outcome). This study also showed improvement in renal architectural distortion (mesangial 
diameter) (p = 0.01) and increase in creatinine clearance (p = 0.02). In a more recent, larger 
RCT, 42% of placebo patients versus 27% of treated patients had clinical events (defined as 
renal, cardiac or cerebrovascular event or death); the time to first clinical event adjusted for 
baseline proteinuria favoured agalsidase beta but included the null (hazard ratio 0.47, CI: 
0.21–1.03; p< 0.06). Although overall the results were less than overwhelming, treatment 
effect was greater in patients with preserved renal function. There are no data currently 
regarding ERT and affect on mortality. 
Moreover, a purified recombinant α-galactosidase A enzyme (Fabrazyme®) was synthesized 
and administration in non-transplanted FD patients was reported to markedly reduce serum 
ceramide levels. A detailed report revealed few serious adverse events in a total of 401 
patients receiving long-term treatment; as in this study, most adverse events consisted of 
mild infusion reactions. Patients given recombinant α-GalA at 1 mg/kg once every two 
weeks showed decreased microvascular endothelial deposits of Gb3 in skin over a period of 
20 weeks and plasma Gb3 also decreased. In addition, in patients who received ERT for 30-
36 months, serum creatinine and estimated glomerular filtration rate values remained stable, 
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while the level of plasma Gb3 remained in a normal range after ERT. More recently, Cybulla 
et al. explored the effects of agalsidase alfa in transplant patients with FD. Allograft function 
of 20 patients from the Fabry Outcome Survey registry was analyzed after approximately 3.5 
years (median) of agalsidase alfa therapy at the standard dose of 0.2 mg/kg every other 
week. After 2 years of ERT, there was a slight but nonsignificant increase in serum 
creatinine (1.4 mg/dl at baseline versus 1.6 mg/dl) and a decrease in eGFR (59.2 
ml/min/1.73 m2 at baseline versus 51.1 ml/min/1.73 m2 at 2 years). Similar to the 
previously mentioned study, proteinuria remained stable during this time period. In 
contrast, ERT may be less effective to improve renal or cardiac function in cases with 
progressive damage to tissue, as it would likely be difficult to recover the function. 
Therefore, renal transplantation in conjunction with ERT might achieve better improvement 
of the graft and overall survival of FD patients. 
Mignani et al. reported that plasma Gb3 was decreased by 23-50% after ERT in renal 
transplant patients with FD. In addition, Inderbitzin et al. treated a patient with persistent 
FD-related acroparesthesia and found that ERT for 100 months after renal transplantation 
resulted in an excellent clinical course. In another study, Mignani et al. also reported 3 
patients who underwent ERT after renal transplantation, who had maintained renal 
function and improved cardiac function. In each of those cases, ERT was performed after 
renal transplantation, whereas we previously reported a rare case of successful cadaveric 
renal transplantation in patient with FD maintained by ERT with an excellent clinical course. 
We treated a 48-year-old male patient with a typical clinical history of FD from childhood 
(intermittent fever, cutaneous angiokeratoma, pain attacks in arms and legs). At the age of 
25, renal function disorder with proteinuria was pointed out and hemodialysis started at 26 
years old. He was diagnosed with FD based on deficient lysosomal α- galactosidase A 
activity at the age of 46 and began ERT by injection of recombinant α-galactosidase e.g. 
Agalsidase beta at 1mg per kg bodyweight once every two weeks in August 2004. After the 
induction of ERT, he still had diffuse angiokeratoma of the body and intermittent abdominal 
pain. Echocardiographic evaluation suggested hypertrophic obstructive cardiomyopathy 
with left ventricular hypertrophy. 
On December 17, 2005, cadaveric renal transplantation was performed (Fig.6) for the patient. 
The initial immunosuppressive agents were cyclosporine, mycophenolate mofetil, steroids, 
and basiliximab, with the cyclosporine trough levels kept at 100-150 ng/ml. No rejection or 
other complications appeared during the immediate follow-up period, and he withdrew 
from hemodialysis 23 days after transplantation. At discharge, serum creatinine was 
reduced to about 1.9 mg/ml and was at a steady-state level. At the same time, the 
disappearance of the skin lesions and abdominal pain was noticed. At 12 and 24 months 
after transplantation, graft biopsies were performed, as the serum creatinine level increased 
to 2.2～2.3 mg/dl. Histological results demonstrated acute cellular rejection, however, there 
were no abnormal deposits of accumulated glycosphingolipids in the glomerular podocytes 
or tubular epithelial cells. Electron microscopy revealed normal glomerular cells with a 
slight increase in the mesangial matrix (Fig.7). 
There were no dense deposits. The acute rejection responded to intravenous 
deoxyspergualin and serum creatinine decreased to 2.0 mg/dl. Since transplantation, ERT 
has been continued once every two weeks and no complications as a result of that therapy 
have been recognized. 
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Fig. 6. Clinical course of the patient. Cr creatinine; CsA, cyclosporine; HD, hemodialysis; 
MMF, mycofenolate mophetil; PSL, predonisolone. 
 
Fig. 7. Electron microscopy of normal glomerulus from kidney graft. Occasional foci of 
podocyte fusion are present. 
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The recurrence of FD in patients with a transplanted kidney has rarely been reported. 
Findings of small amounts of Gb3 deposits in renal grafts have been limited to vascular 
endothelial cells and tubular epithelial cells. We consider that renal transplantation 
combined with ERT reduces the risk of recurrence of FD in a transplanted kidney. However, 
further data are required to confirm whether such treatment will confer long-term 
renoprotective effects on renal transplantation. 
An important problem facing FD patients is that a successful kidney graft survives for 10-15 
years, however, cardiovascular complications related to metabolic disease may occur during 
that time. FD generally progresses systemically after renal transplantation and cardiac 
ceramide deposition ultimately determines the fate of these patients in the second decade 
after renal transplantation. Since ERT improves cardiac involvement in FD patients, renal 
transplantation combined with ERT may be the best therapy for ESRD at the present time. 
Additional clinical studies are needed to determine the effects of this combination on the 
overall prognosis of FD. 
5. Conclusion  
Renal transplantation is effective for FD and improves patient and graft survivals as well as 
overall prognosis in patients with ESRD due to FD. And ERT is well tolerated in patients 
with FD who have undergone renal transplantation. 
In summary, some studies indicate that kidney transplantation and ERT are viable option 
for patients with ESRD due to FD. Although ERT appears to stabilize renal function, further 
data are required to confirm whether such treatment will confer long-term renoprotective 
effects on kidney transplant patients. 
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